Additional L-Carnitine Reduced the Risk of Hospitalization in Patients with Overt Hepatic Encephalopathy on Rifaximin
| Autor: | Kousuke Kubota, Naohisa Wada, Takahide Nakazawa, Shuichiro Iwasaki, Wasaburo Koizumi, Hisashi Hidaka, Xue Shao, Haruki Uojima, Akitaka Shibuya, Makoto Kako |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Liver Cirrhosis
medicine.medical_specialty business.industry Gastroenterology MEDLINE General Medicine medicine.disease Rifamycins Rifaximin Hospitalization chemistry.chemical_compound chemistry Carnitine Hepatic Encephalopathy Internal medicine medicine Humans In patient business Hepatic encephalopathy medicine.drug |
| Zdroj: | Digestive Diseases. 40:313-321 |
| ISSN: | 1421-9875 0257-2753 |
| Popis: | Background: Data regarding the additional effect on the recurrence of hepatic encephalopathy (HE) after oral L-carnitine administration are scarce. Objective: This study aimed to assess the additional effects of L-carnitine in patients who were receiving rifaximin for HE. Methods: This randomized study comprised a screening visit and a 12-week treatment period. Patients who fulfilled the eligibility criteria were randomized to either group A (additional rifaximin) or group B (additional L-carnitine and rifaximin). Group A received 1,200 mg/day of rifaximin. Group B received 1,500 mg/day of L-carnitine and rifaximin at 1,200 mg/day. The endpoints were the changes in the portal systemic encephalopathy (PSE) index and the admission rate from the baseline for the duration of the study in both groups. Results: Eighty-three patients were randomized to either group A (n = 42) or group B (n = 41). In group A, the PSE index decreased from 0.35 ± 0.09 at baseline to 0.27 ± 0.11 on the final evaluation day (p = 0.001). In group B, the PSE index decreased from 0.37 ± 0.09 at baseline to 0.24 ± 0.11 on the final evaluation day (p = 0.001). Although there was not a significant reduction in the PSE index in group A compared to that in group B (p = 0.202), the admission rates were 30.9% and 9.8% in groups A and B, respectively. Additional L-carnitine significantly reduced the admission rate (p = 0.028). Conclusion: L-Carnitine addition reduced the risk of hospitalization for patients who received rifaximin for HE. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|